Apple's iPhone 17 and AirPods Pro 3 have only just been revealed, but ESR already has a suite of cases, screen protectors, and MagSafe chargers ready for the second you open the new products. ESR is ...

If you’ve picked up a new iPhone 17, you’ll want more than basic protection. The best cases not only guard against drops but also add features that enhance daily use. ESR’s Stash Stand Cases and ...

Stand cases and wireless chargers that provide protection all around and peak performance can improve your iPhone experience. When you purchase through links on our site, we may earn an affiliate ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Generally people equate the Arduino hardware platforms with MCU-centric options that are great for things like low-powered embedded computing, but less for running desktop operating systems. This ...

The IMF’s 2018 ESR shows that global current account balances stand at about 3¼ percent of global GDP. Of this, 40-50 percent are now deemed excessive, i.e. some countries are saving too much, and ...

Overall current account deficits and surpluses narrowed modestly in 2019 to just under 3 percent of world GDP. The IMF’s multilateral approach suggests that about 40 percent of overall current account ...

Sponsored Content. We may receive a commission on purchases made from links. The launch of the new iPhone 17 marks a significant step into the next generation of smartphones, with many remarking that ...

Determining whether ESR Cayman Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ESR ...

Two new human resources tech stocks are hatching plans to debut on the ASX in 2016, aiming to recreate the stellar performance of 1-Page and Reffind. The clock is ticking for Sundance Resources to ...

Inluriyo is the second oral therapy approved for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, offering an alternative to injectable endocrine therapies. The Phase III EMBER-3 trial ...